|Brand name(s), other common name(s)||XpovioTM|
|Drug type||SINE (Selective Inhibitor of Nuclear Export) Compound (this is a first-in-class SINE compound)|
|How the drug is given||Oral|
Indications and Usage
Selinexor is FDA approved in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Side effects needing medical attention
Thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infections.